Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.
作者信息
Berger Karin C, Feldman Brian M, Wasserman Joan, Schramm Wolfgang, Blanchette Victor, Fischer Kathelijn
机构信息
University Hospital of Munich, Department of Haematology/Oncology, Germany
Division of Rheumatology, and The Research Institute, The Hospital for Sick Children, Department of Paediatrics, Medicine, and IHPME, University of Toronto, Canada.
出版信息
Haematologica. 2016 Mar;101(3):266-8. doi: 10.3324/haematol.2015.139931.
Abstract
摘要
相似文献
1
Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.确保以患者为中心的血友病护理获得报销：需要重大的协作努力。
Haematologica. 2016 Mar;101(3):266-8. doi: 10.3324/haematol.2015.139931.
2
Economic aspects of haemophilia care.
Haemophilia. 1999 May;5(3):216-9. doi: 10.1046/j.1365-2516.1999.00325.x.
3
Outcome measures in haemophilia: more than just factor levels.
Haemophilia. 2004 Mar;10 Suppl 1:2-8. doi: 10.1111/j.1355-0691.2004.00873.x.
4
[The use of coagulation factors in hemophilia treatment].
Pharm Unserer Zeit. 2006;35(1):66-73. doi: 10.1002/pauz.200500157.
5
Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution.单一机构中肥胖对重度血友病儿童凝血因子预防治疗的药物经济学影响
Haemophilia. 2011 Jul;17(4):717-8. doi: 10.1111/j.1365-2516.2010.02462.x. Epub 2011 Feb 16.
6
Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.在轻度至中度出血情况下，重组活化因子 VII 与血浆源性活化凝血酶原复合物浓缩物的经济学分析：来自捷克共和国的血友病登记数据。
Thromb Res. 2012 May;129(5):e233-7. doi: 10.1016/j.thromres.2012.02.005. Epub 2012 Mar 2.
7
Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
Haemophilia. 2010 Mar;16(2):366-8; discussion 369-71. doi: 10.1111/j.1365-2516.2009.02117.x. Epub 2009 Oct 6.
8
Towards a partnership of care for patients with haemophilia.
N Z Med J. 2003 Dec 12;116(1187):U721.
9
High cost, low volume care: the case of haemophilia.
BMJ. 1997 Oct 18;315(7114):962-3. doi: 10.1136/bmj.315.7114.962.
10
Purchasing factor concentrates in the 21st century through competitive tendering.21 世纪通过竞争性招标集中采购要素。
Haemophilia. 2013 Sep;19(5):660-7. doi: 10.1111/hae.12169. Epub 2013 May 28.
引用本文的文献
1
Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies.Kreuth V 倡议：使用标准产品、延长半衰期凝血因子浓缩物和非替代疗法治疗血友病的欧洲共识建议。
Haematologica. 2020 Aug;105(8):2038-2043. doi: 10.3324/haematol.2019.242735. Epub 2020 May 28.
2
Strategies for eliciting and synthesizing evidence for guidelines in rare diseases.为罕见病指南制定证据收集和综合策略。
BMC Med Res Methodol. 2019 Mar 28;19(1):67. doi: 10.1186/s12874-019-0713-0.
本文引用的文献
1
Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.增强半衰期因子 VIII 和 IX 在血友病治疗中的作用。
Br J Haematol. 2015 Jun;169(6):768-76. doi: 10.1111/bjh.13360. Epub 2015 Mar 7.
2
Comparative effectiveness research in oncology methodology: observational data.肿瘤学方法中的比较疗效研究：观察性数据。
J Clin Oncol. 2012 Dec 1;30(34):4215-22. doi: 10.1200/JCO.2012.41.6701. Epub 2012 Oct 15.
3
Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.前瞻性观察性研究评估比较有效性：ISPOR 良好研究实践工作组报告。
Value Health. 2012 Mar-Apr;15(2):217-30. doi: 10.1016/j.jval.2011.12.010.
4
Can observational studies approximate RCTs?
Value Health. 2012 Mar-Apr;15(2):215-6. doi: 10.1016/j.jval.2012.01.003. Epub 2012 Feb 18.
5
Translating comparative effectiveness research into clinical practice: the UK experience.将比较效果研究转化为临床实践：英国的经验。
Drugs. 2012 Jan 22;72(2):163-70. doi: 10.2165/11630860-000000000-00000.
6
The methods of comparative effectiveness research.比较疗效研究的方法。
Annu Rev Public Health. 2012 Apr;33:425-45. doi: 10.1146/annurev-publhealth-031811-124610. Epub 2012 Jan 3.
7
GRADE guidelines: 3. Rating the quality of evidence.GRADE 指南：3. 评估证据质量。
J Clin Epidemiol. 2011 Apr;64(4):401-6. doi: 10.1016/j.jclinepi.2010.07.015. Epub 2011 Jan 5.
8
EUHASS: The European Haemophilia Safety Surveillance system.欧盟血友病安全监测系统。
Thromb Res. 2011 Jan;127 Suppl 2:S22-5. doi: 10.1016/S0049-3848(10)70150-X.
9
Comparative effectiveness research: Policy context, methods development and research infrastructure.比较疗效研究：政策背景、方法发展与研究基础设施。
Stat Med. 2010 Aug 30;29(19):1963-76. doi: 10.1002/sim.3818.
10
GRACE principles: recognizing high-quality observational studies of comparative effectiveness.GRACE 原则：识别高质量的比较有效性观察性研究。
Am J Manag Care. 2010 Jun;16(6):467-71.
Zotero 插件